The FDA has approved Akeso's PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of recurrent or metastatic non-keratinising nasopharyngeal carcinoma in adults. The approval includes its use as a first-line treatment in combination with platinum-based chemotherapy, as well as a...
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market .. DelveInsight )
Also on site :
- Kremlin comments on possible US strike on Iran
- Nazi symbols prevalent in Ukrainian military – Le Monde
- 'Gossip Girl' Star Admits He’s Never Rewatched the Series: ‘It’s Embarrassing’